Insugen 50/50 Injection 40IU/ml is a premixed insulin formulation containing 50% insulin isophane (NPH insulin) and 50% human insulin, designed for the management of diabetes mellitus requiring insulin therapy. This biphasic insulin preparation combines intermediate-acting insulin isophane, which provides prolonged glycemic control, with rapid-acting soluble human insulin, facilitating prompt reduction of postprandial blood glucose levels. Insugen 50/50 is indicated for patients with type 1 diabetes mellitus or type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not achieve adequate glycemic control. The insulin is administered subcutaneously, typically before meals, to optimize blood glucose regulation. Dosage and timing should be individualized based on the patient’s metabolic needs, blood glucose monitoring results, and lifestyle. Caution is advised to avoid hypoglycemia, the most common adverse effect, which may present with symptoms such as sweating, tremors, and confusion. Patients should be educated on recognizing and managing hypoglycemia and the importance of adherence to prescribed regimens. Insugen 50/50 Injection should be stored under recommended conditions to maintain potency. It is contraindicated in patients with hypersensitivity to insulin or any excipients in the formulation. Regular monitoring of blood glucose and periodic assessment of glycemic control are essential for safe and effective therapy.